購物車 
-
Gitoformate
- names：
Gitoformate
- CAS號：
10176-39-3
MDL Number： - MF(分子式)： C46H64O19 MW(分子量)： 921
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 貨品編碼 | 規(guī)格 | 純度 | 價格 (￥) | 現(xiàn)價(￥) | 特價(￥) | 庫存描述 | 數量 | 總計 (￥) |
|---|
| 中文別名 | (2R,3R,4S,6S)-6-(((2R,3R,4S,6S)-4-(formyloxy)-6-(((2R,3R,4S,6R)-4-(formyloxy)-6-(((3S,5R,8R,9S,10S,13R,14S,16S,17R)-16-(formyloxy)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2,5-dihydrofuran-3-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-2-methyltetrahydro-2H-pyran-3-yl)oxy)-2-methyltetrahydro-2H-pyran-3-yl)oxy)-2-methyltetrahydro-2H-pyran-3,4-diyl diformate |
| 英文別名 | Gitoformate; Formiloxin; Pentaformylgitoxin; AC 2770 |
| CAS號 | 10176-39-3 |
| Inchi | InChI=1S/C46H64O19/c1-24-41(59-23-51)32(55-19-47)14-38(60-24)64-43-26(3)62-39(16-34(43)57-21-49)65-42-25(2)61-37(15-33(42)56-20-48)63-29-8-10-44(4)28(13-29)6-7-31-30(44)9-11-45(5)40(27-12-36(52)54-18-27)35(58-22-50)17-46(31,45)53/h12,19-26,28-35,37-43,53H,6-11,13-18H2,1-5H3/t24-,25-,26-,28-,29+,30+,31-,32+,33+,34+,35+,37+,38+,39+,40+,41-,42-,43-,44+,45-,46+/m1/s1 |
| InchiKey | DOMHWKQEPDYUQX-LJAQBGIBSA-N |
| 分子式 Formula | C46H64O19 |
| 分子量 Molecular Weight | 921 |
| 溶解度Solubility | |
| 性狀 | Solid powder |
| 儲藏條件 Storage conditions | Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years). |
| 產品說明 | Gitoformate(CAS:10176-39-3):僅限應用于工業(yè)或者科學研究過程中非醫(yī)療目的，不應用于人類或動物的臨床診斷以及治過程療，該產品非藥用，非食用。 |
| Introduction | Gitoformate is used to treat cardiac and renal insufficiency, |
| Application1 | |
| Application2 | |
| Application3 |
| [1]Kubin S, Woodcock BG, Menke G, Rietbrock N. [Postprandial delay of drug absorption in a gitoformate model]. Arzneimittelforschung. 1987 Dec;37(12):1376-8. German. PubMed PMID: 3449065. |
| [2]Reuter N, Meyer F. [Effects of pentaformylgitoxin (gitoformate) on the cardiovascular system of anesthetized cats]. Arzneimittelforschung. 1976;26(6):1201-5. German. PubMed PMID: 989416. |
| [3] Dei Cas L, Manca C, Assanelli D, Vasini G, Pelagatti T, Buia E. [Pharmacokinetics and pharmacodynamics of gitoformate in subjects with atrial fibrillation]. Boll Soc Ital Cardiol. 1981;26(12):2383-4. Italian. PubMed PMID: 7185409. |
| [4] Dei Cas L, Vasini G, Manca C, Buia E, Pelagatti T, Bernardini B. [Pharmacokinetics of gitoformate in subjects with renal insufficiency under dialysis treatment]. Boll Soc Ital Cardiol. 1981;26(12):2381-2. Italian. PubMed PMID: 7185408. |
| [5] Lesne M, Cremers S, Carlier J. [Pharmacokinetic and biopharmaceutic parameters of gitoformate]. Therapie. 1978 Nov-Dec;33(6):723-34. French. PubMed PMID: 746519. |
6: Rietbrock N, Woodcock BG, Hrazdil U. [Gitoformate and digitoxin as alternatives to kidney-dependent glycosides in the therapy of cardiac insufficiency]. Arzneimittelforschung. 1984;34(8):915-7. German. PubMed PMID: 6541927.7: Dei Cas L, Vasini G, Bianchi G, Manca C, Ghinelli R, Mansour M. [Gitoformate in chronic renal insufficiency: pharmacokinetic aspects]. Boll Soc Ital Cardiol. 1979;24(2):209-12. Italian. PubMed PMID: 548097.8: Dei Cas L, Biasucci LM, Buia E, Frustaci A, Manca C, Metra M, Rebuzzi AG. [Circadian aspects of the heart rate in atrial fibrillation patients: the comparative effect of digoxin and pentaformylgitoxin]. Cardiologia. 1983 Dec;28(12):1019-25. Italian. PubMed PMID: 6681261.9: Kesteloot H, Brasseur L, Carlier J, Demanet JC, Andriange M, Bataille G, Collignon P, Cosyns J, Vancrombreucq JC, Van Durme JP, Willems J, Foucart G. Effect of digitalis on the left ventricular ejection time: a multicenter double-blind comparative study of digitoxin and pentaformylgitoxin in normal subjects. Acta Cardiol. 1969;24(4):409-25. PubMed PMID: 4928444.10: Dei Cas L, Biasucci LM, Buia E, Frustaci A, Manca C, Metra M, Rebuzzi AG. [Circadian aspects of heart rate in patients with atrial fibrillation: comparative influence of digoxin and pentaformylgitoxin]. Cardiologia. 1983 Dec;28(12):1019-25. Italian. PubMed PMID: 6687204.1
對不起，暫無產品評價！
MSDS
SDS 1.0 中文
展開
SDS 1.0 英文
展開
- 相關產品
-
< >
- 推薦產品
-
< >
- 最新產品
-
< >
新聞
怎么做細胞爬片免疫組化染色實驗
細胞爬片免疫組化染色，是通過細胞爬片是讓玻片浸在細胞培養(yǎng)基內，細胞在玻片上生長，主要用于組織學，免疫組織化學...
2020/7/20 22:04:33
提取病毒RNA的實驗方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
細胞培養(yǎng)耗材技術領先性
細胞培養(yǎng)板行業(yè)面臨的核心痛點是：常規(guī)TC處理后表面親水角隨時間衰減，影響長期培養(yǎng)穩(wěn)定性，BIOFOUNT高分...
2026/4/28 15:12:51
板.jpg)
細胞培養(yǎng)耗材關鍵性能
細胞培養(yǎng)板的水接觸角作為表面潤濕性的核心指標，直接影響細胞貼壁、增殖、分化及功能表達，其中40°（低接觸角/...
2026/4/28 14:52:44
chelex 100樹脂國產替代之路-BIOFOUNT范德生物
Chelex 100螯合離子交換樹脂對銅、鐵和其他重金屬?的偏好顯著高于對鈉、鉀等一價陽離子的偏好。它對二價...
2025/11/4 14:22:46
9月開學季——助研新學期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實驗室封口膜：技術與國際市場的雙重突破
在實驗室耗材領域，封口膜是保障實驗準確性與穩(wěn)定性的關鍵產品之一。近年來，Waxfilm?實驗室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實驗室封口膜的5大突破
Waxfilm實驗室封口膜作為生物功能膜領域的國產技術突破和品牌突破，是生物領域中國技術發(fā)展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優(yōu)缺點
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優(yōu)缺點。本文主要介紹聚酯...
2023/7/28 10:43:09
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個重要環(huán)節(jié)，也是最容易被忽視的--芯片鍵合。其中一個重要因素是：微流控...
2023/7/27 12:44:28
